14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SLNO vs ZLAB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Soleno Therapeutics, Inc. (SLNO) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SLNO carries a Unified Composite Score of 44.5/100 (HOLD) at $53.01 (8.4x Forward P/E, 33.6% operating margin), whereas ZLAB carries 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin).
Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. SLNO 44.5/100 HOLD), SLNO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (33.6% vs. -63.0% operating margin) and revenue trajectory (+0.0% vs. -6.8% YoY).
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SLNO vs ZLAB. Trailing 12-month operating profitability (SLNO 33.6% vs ZLAB -63.0%) and valuation multiples (SLNO 8.4x vs ZLAB N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $3.0B market capitalization and -63.0% operating margin.
OpEx & R&D Reinvestment63.6% of Rev ($281M)
90D Engineering Disclosures0 Published
Investor FAQ SLNO vs ZLAB Key Questions & Quantitative Answers
As of Nov 16, 2026, Soleno Therapeutics, Inc. (SLNO) is the stronger overall head-to-head candidate over Zai Lab Limited (ZLAB) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). SLNO carries a Unified Composite Score of 44.5/100 (HOLD) at $53.01 (8.4x Forward P/E, 33.6% operating margin), whereas ZLAB carries 47.4/100 (HOLD) at $23.83 (N/M Forward P/E, -63.0% operating margin). Composite vs. Pillar Nuance: While ZLAB currently prints a higher short-term Unified Composite Score (47.4/100 HOLD vs. SLNO 44.5/100 HOLD), SLNO captures the overall institutional head-to-head verdict (7–3 matrix metrics and 5–1 across the 6 pillars) due to superior fundamental profitability (33.6% vs. -63.0% operating margin) and revenue trajectory (+0.0% vs. -6.8% YoY).
ZLAB leads the Growth & Scale pillar: SLNO posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on $285M TTM revenue (98.6% gross margin, 33.6% operating margin), compared with ZLAB at -6.8% YoY revenue growth and +0.0% YoY earnings growth on $442M TTM revenue (0.6% gross margin, -63.0% operating margin). On trailing 12-month operating scale, SLNO generates $285M in USD-normalized revenue versus $442M for ZLAB. In operating R&D and SG&A reinvestment, SLNO deploys 65.0% of Rev ($185M) (0 90-day corporate R&D disclosures) versus 63.6% of Rev ($281M) (0 disclosures) for ZLAB.
SLNO screens cheaper on headline valuation multiples. SLNO trades at 8.4x Forward P/E, 27.5x Trailing P/E, N/M PEG, and 9.7x EV/Revenue (32.1% EBITDA margin), whereas ZLAB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and 6.8x EV/Revenue (-59.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SLNO (26.4% ROE) versus ZLAB (-30.0% ROE) capital efficiency.
In options market volatility and institutional positioning, SLNO carries 0.9% implied volatility (<1st %ile, Compressed (<25th %ile)), a 5.23x (Put-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.23β · 2% Vol realized risk). By comparison, ZLAB carries 58.4% implied volatility (58th %ile, Balanced (25th–60th %ile)), thin ADR options open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.19β · 78% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.